Abbisko will debut two blockbuster clinical research results at the 2023 European Society for Medical Oncology(ESMO)
- Written by PR Newswire
SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that the clinical results of first-in-human study of FGFR4 inhibitor Irpagratinib(ABSK011)and the clinical results of first-in-human dose-escalating of PD-L1 inhibitor ABSK043 with advanced...














